The effect of new and continuing prescription drug use on cost: A longitudinal analysis of chronic and seasonal utilization

Clinical Therapeutics

Volumn 22, Issue 5, 2000, Pages 641-652

  Fairman, Kathleen A ^a  

^a Express Scripts   (United States)

Author keywords

Cost; Drugs; Evidence based benefit design; Utilization

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTILIPEMIC AGENT; ANTIRHEUMATIC AGENT; ANTIULCER AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUTYROPHENONE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; HALOPERIDOL; LOXAPINE; METFORMIN; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PHENOTHIAZINE DERIVATIVE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; THIOXANTHENE DERIVATIVE; UNINDEXED DRUG;

ARTICLE; COST CONTROL; DRUG CLASSIFICATION; DRUG COST; DRUG UTILIZATION; FINANCIAL MANAGEMENT; HEALTH CARE PLANNING; HEALTH INSURANCE; MANAGED CARE; MEDICARE; PRESCRIPTION; SEASONAL VARIATION;

EID: 0033936343     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80051-X     Document Type: Article

References (20)

1. 1. Mehl B, Santell JP. Projecting future drug expenditures-1999. Am J Health-Syst Pharm. 1999;56:31-39.
2. 2. Navarro RP. Dissecting drug cost trends. Med Interface. 1997;10:80-82.
3. 3. Teitelbaum F, Parker A, Martinez R, Roe C. Express Scripts Drug Trend Report. St. Louis, Mo: Express Scripts, Inc; 1999: 2-3, 12, 23-24, 39.
4. 4. Braden BR, Cowan CA, Lazenby HC, et al, for the US Health Care Financing Administration, Office of the Actuary. National health expenditures, 1997. Health Care Financ Rev. 1998;20:83-126.
5. 5. Kane NM. Pharmaceutical cost containment and innovation in the United States. Health Policy. 1997;41(Suppl):S71-S89.
6. 6. Kozma CM. The effect of new pharmaceutical agents on pharmacy budgets. Manag Care Interface. 1999;12:77-78.
7. 7. McCarthy R. A behind-the-numbers look at rising Rx costs. Bus Health. 1998;16: 29, 32-35.
8. 8. Ryan BA. The rising cost of pharmaceuticals: An industry observer's perspective. Am J Health-Syst Pharm. 1993;50(Suppl 4):S3-S4.
9. 9. Lyles A, Palumbo FB. The effect of managed care on prescription drug costs and benefits. Pharmacoeconomics. 1999; 15: 129-140.
10. 10. Public Citizen's Health Research Group. Comments on: Food and Drug Administration: Attitudinal and behavioral effects of direct-to-consumer advertising of prescription drugs. HRG Publication #1460. Submitted on September 28, 1998. Available at: www.citizen.org/hrg/publications/ 1460.htm. Accessed February 28, 2000.
11. 11. Lipsky MS, Taylor CA. The opinions and experiences of family physicians regarding direct-to-consumer advertising. J Fam Pract. 1997;45:495-499.
12. 12. Bloom BS, Jacobs J. Cost effects of restricting cost-effective therapy. Med Care. 1985;23:872-880.
13. 13. Burstall ML. Copayments for medicines: How much should patients pay? Pharmacoeconnmics. 1994;6:187-192.
14. 14. Levy RA. Prescription cost sharing: Economic and health impacts, and implications for health policy. Pharmacoeconomics. 1992;2:219-237.
15. 15. Soumerai SB, Ross-Degnan D, Fortess EE, Abelson J. A critical analysis of studies of state drug reimbursement policies: Research in need of discipline. Milbank Q. 1993;71:217-252.
16. 16. Mason J, Freemantle N. The dilemma of new drugs: Are costs rising faster than effectiveness? Pharmacoeconomics. 1998;13: 653-657.
17. 17. Winslow R. Copayments rise for prescriptions. Wall Street Journal. January 12, 1999:B1, B4.
18. 18. Medi-Span. Generic Product Identifier. Indianapolis, Ind: Medi-Span; 1998.
19. 19. Weiss K, Gergen P, Wagener D. Breathing better or wheezing worse? The changing epidemiology of asthma morbidity and mortality. Annu Rev Public Health. 1993; 14:493-494.
20. 20. Stephenson BJ, Rowe BH, Haynes MB, et al. Is this patient taking the treatment as prescribed? JAMA. 1993;269:2779-2781.